Replies to post #172074 on Biotech Values

[bladerunner1717]

Thanks for that.

Bladerunner

[north40000]

I find both your alphabetical list as well as top% gain to least list valuable now. The 2 lists show us where we have been, and particularly what we missed. Looking out longer term in the past, not just calendar year 2013, I find my gains differ quite a bit from those reflected in the tables---GILD
and CLDX come to mind on the + side.

Thank you for assembling both lists.

[DewDiligence]

2013 IPOs aren't on your list. Also, where's AMRN?

[read_this_n0w]

Northwest Biotherapeutics (NWBO) Said GBM Brain Cancer Trial Recommend To Continue

company announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned.

The DSMB's review of the efficacy data is still pending.

Dr. Marnix Bosch, Chief Technical Officer of NW Bio noted, "We are pleased with the recommendation of the DSMB to continue the trial as planned. This is an important step in the ongoing progress of our Phase III trial."